References
- Bajjoka I, Patel T, O'Sullivan T. Risperidone-induced neuroleptic malignant syndrome. Annals of Emergency Medicine 1997; 30: 698–700
- Chatterton R, Cardy S, Schramm M. Neuroleptic malignant syndrome and clozapine monotherapy. Australian and New Zealand Journal of Psychiatry 1996; 30: 692–693
- Amore M, Zazzeri N, Berardi D. Atypical neuroleptic malignant syndrome associated with clozapine treatment. Neuropsychobiology 1997; 35: 197–199
- Bonwick RJ, Hopwood MJ, Morris P LP. Neuroleptic malignant syndrome and risperidone: A case report. Australian and New Zealand Journal of Psychiatry 1996; 30: 419–421
- Eli Lilly and Co. Product monograph zyprexa (Olanzapine). Eli Lilly, Sydney 1997
- Bristow M, Kohen D. Neuroleptic malignant syndrome. British Journal of Hospital Medicine 1996; 55: 517–520
- Pope H, Keck P, McElroy S. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. American Journal of Psychiatry 1986; 143: 1227–1232
- Cohen WJ, Cohen NH. Lithium carbonate, haloperidol and irreversible brain damage. Journal of the American Medical Association 1974; 230: 1283–1287
- Swanson C, Price W, McEvoy J. Effect of concomitant risperidone and lithium treatment. American Journal of Psychiatry 1995; 152: 1096